Remove Engineering Remove Protein Expression Remove Protein Production
article thumbnail

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

Upstream cell line development has seen notable progress with recent advances in cell line engineering, particularly in enhancing gene of interest integration specificity, clone selection, and production efficiency. Next-generation engineering tools, such as gene editing have enabled knock-out cell lines with enhanced characteristics.

article thumbnail

Driving efficiency across upstream bioprocess workflow

Drug Target Review

Advancements in genetic and protein engineering through technology innovation, automation, and more recently machine learning, have led to the development of more complex molecules such as bispecific antibodies and antibody drug conjugates. References Mistry RK, Kelsall E, Sou SN, et al. Budge JD, Knight TJ, Povey J, et al.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. from engineered peptide and antibody libraries’. Harriman will present ‘Discovering functional modulators of the ion channel Kv1.3

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

article thumbnail

Finding the right CDMO partner for cell line development

Drug Target Review

Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. They’re prepared for complexity Successful expression of the gene of interest is not sufficient on its own for large-scale production.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It Sphere Fluidics presence on the exhibition floor was bolstered by a presentation from Richard Hammond: ‘Picodroplets for cell Line engineering: A novel automation approach’.